1. Home
  2. NMRA vs AQST Comparison

NMRA vs AQST Comparison

Compare NMRA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • AQST
  • Stock Information
  • Founded
  • NMRA 2019
  • AQST 2004
  • Country
  • NMRA United States
  • AQST United States
  • Employees
  • NMRA N/A
  • AQST N/A
  • Industry
  • NMRA
  • AQST Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMRA
  • AQST Health Care
  • Exchange
  • NMRA Nasdaq
  • AQST Nasdaq
  • Market Cap
  • NMRA 287.6M
  • AQST 274.4M
  • IPO Year
  • NMRA 2023
  • AQST 2018
  • Fundamental
  • Price
  • NMRA $1.23
  • AQST $2.89
  • Analyst Decision
  • NMRA Buy
  • AQST Strong Buy
  • Analyst Count
  • NMRA 8
  • AQST 7
  • Target Price
  • NMRA $10.14
  • AQST $10.57
  • AVG Volume (30 Days)
  • NMRA 1.3M
  • AQST 1.5M
  • Earning Date
  • NMRA 03-03-2025
  • AQST 03-05-2025
  • Dividend Yield
  • NMRA N/A
  • AQST N/A
  • EPS Growth
  • NMRA N/A
  • AQST N/A
  • EPS
  • NMRA N/A
  • AQST N/A
  • Revenue
  • NMRA N/A
  • AQST $57,561,000.00
  • Revenue This Year
  • NMRA N/A
  • AQST N/A
  • Revenue Next Year
  • NMRA N/A
  • AQST $35.72
  • P/E Ratio
  • NMRA N/A
  • AQST N/A
  • Revenue Growth
  • NMRA N/A
  • AQST 13.80
  • 52 Week Low
  • NMRA $1.26
  • AQST $2.24
  • 52 Week High
  • NMRA $17.19
  • AQST $6.23
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 28.48
  • AQST 47.99
  • Support Level
  • NMRA $1.26
  • AQST $2.45
  • Resistance Level
  • NMRA $1.48
  • AQST $3.06
  • Average True Range (ATR)
  • NMRA 0.13
  • AQST 0.20
  • MACD
  • NMRA 0.08
  • AQST 0.03
  • Stochastic Oscillator
  • NMRA 10.99
  • AQST 60.66

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Share on Social Networks: